Research outlook

Where FSGS treatment is heading

FSGS · Updated Nov 14, 2026

Focal segmental glomerulosclerosis (FSGS) is a pattern of kidney scarring that starts with damage to podocytes, the cells that keep protein out of the urine. About 5,000 Americans are diagnosed each year, and it is a leading cause of kidney failure in young people; causes include immune factors, genes (including APOL1 variants common in people of African ancestry) and other conditions. Steroids and other immunosuppressants help only some patients. In April 2026 sparsentan became the first drug approved for FSGS, and drugs that directly protect podocytes are now in phase 3.

  1. Now

    Nov 2026

    The first FSGS approvalHappened 42.0% partial remission

    Sparsentan raised partial remission of proteinuria vs irbesartan (42.0% vs 26.0%); FDA approved April 2026.

    42.0%: partial remission of proteinuria at 36 weeks, vs 26.0%.

    Protecting podocytes directlyHappened 35% proteinuria response

    A TRPC6 blocker lowered proteinuria in 35% of patients vs 7% with placebo.

    35%: proteinuria response across doses, vs 7% with placebo.

    Finerenone adds protectionHappened 42% less albuminuria

    In glomerular diseases including FSGS, finerenone cut albuminuria by 42% and slowed kidney function loss.

    42%: reduction in albuminuria at 12 months.

  2. 6 months

    by May 2027

    Immune-targeted drugsPossible

    Sanofi's trial of frexalimab, brivekimig and rilzabrutinib (84 people) finishes December 2026.

  3. 12 months

    by Nov 2027

    Sparsentan in practiceLikely

    Uptake of the first approved drug, including in genetic FSGS, where immune drugs rarely work.

    A podocyte antibodyPossible

    Walden's WAL0921 (96 people) is due March 2027.

  4. 3 years

    by late 2029

    TRPC6 blocker phase 3Possible 35% proteinuria response (phase 2)

    Boehringer's BI 764198 phase 3 (286 people) is due December 2028.

    35%: proteinuria response across doses, vs 7% with placebo.

    Treating childrenPossible

    Sparsentan is being tested in children with protein-leaking kidney diseases.

  5. 5 years

    by late 2031

    Complement blockadeLong shot

    Apellis' pegcetacoplan phase 2/3 (270 people) is due October 2029.

    Treatment by causeLong shot

    Anti-nephrin antibodies, APOL1 genotype and other markers may sort patients toward immune, genetic or podocyte-targeted treatment.

Happened Likely Possible Long shot

The research paths

Rising

Dual blockers and kidney protection

42.0% partial remission
Details and 2 trialsHide
Rising

Podocyte-targeted drugs

35% proteinuria response
Details and 3 trialsHide
Active

Immune and complement drugs

Details and 3 trialsHide

Borrowed from other conditions

From Diabetic kidney disease and heart failure

Finerenone

Phase 3 analysis

A mineralocorticoid receptor blocker approved for kidney disease with diabetes.

From PNH and geographic atrophy

Pegcetacoplan

Phase 2/3

A complement C3 blocker approved for a blood disease and an eye disease.

From Immune thrombocytopenia

Rilzabrutinib

Phase 2

A BTK inhibitor approved for ITP in 2025.

Open to join now

See every recruiting FSGS trial →

When the trials finish

Completion dates the trials registered. Results usually follow 3 to 12 months later.

2026202720282029203020312032Today
Frexalimab, brivekimig or rilzabrutinibImmune and complement drugs
Dec 2026
Sparsentan in childrenDual blockers and kidney protection
Mar 2027
Mar 2027
PraliciguatDual blockers and kidney protection
Jun 2027
Metformin (AMP-FSGS)Podocyte-targeted drugs
Nov 2027
BI 764198 vs placeboPodocyte-targeted drugs
Dec 2028
Oct 2029
Oct 2030

What just happened

FDA approves sparsentan, first drug for FSGS

Based on DUPLEX.

TRPC6 blocker lowers proteinuria

The Lancet.

Standard treatment today

How to read this page, and sourcesHow to read this page, and sources

See FSGS trials recruiting now →

Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.